The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
The Danish biotech company confirmed the global study will begin in the second half of 2026
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The initiative is designed to benefit patients as well as healthcare providers by streamlining access to consultations, diagnostics, and essential care services
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Subscribe To Our Newsletter & Stay Updated
